Project MATLINK: Development and Evaluation of a Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program for Opioid Dependent Prisoners and Probationers Transitioning to the Community

NCT04947475 | Completed

• 2 other identifiers: 14070143742R01DA029910-06
• Study Type: interventional
• Target: 835
• Locations: 3 countries
• Sites: 3

Brief Summary

The purpose of this study is to evaluate the efficacy a Screening, Brief Intervention, and Referral to Treatment (SBIRT) program for linking opioid dependent individuals currently incarcerated or in probation in Moldova, Kyrgyzstan, and Ukraine to opioid substitution therapy in the community after release or during their probation period.

Conditions

Opioid-use Disorder; HIV Infections; Tuberculosis; Hepatitis C; Hepatitis B; Depression; Syphilis

Keywords

HIV; OUD; Methadone; HCV; HBV; TB; Depression; Syphilis

Outcome Measures

Primary Outcomes (1)

• Enrollment on OAT

  Total number of participants who enroll on OAT divided by the number of participants who underwent study procedures, per country.

  12 months

Secondary Outcomes (5)

• OAT Knowledge

  6 month

• OAT Attitudes

  6 months

• Interest in OAT

  6 months

• OAT Difficulty

  6 months

• OAT Importance

  6 months

Study Arms (1)

Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program

EXPERIMENTAL

There are two objectives to the Brief Intervention. First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder.

Behavioral: SBIRT

Interventions

SBIRT BEHAVIORAL

First, the BI is designed to inform potential participants on the risks of substance misuse, abuse, and dependency by illustrating the potential hazards and adverse health consequences. Second, the BI aims to motivate potential participants to reduce risky behavior (e.g., continued drug use) and seek treatment for their substance dependence disorder. In our BI, we will provide evidence-based information on Opioid Agonist Therapy (OAT) that is available to them in the community upon release or in the community. We will inform them of the risks and benefits of OAT and explain to them how OAT can be accessed in the community. OAT is provided at no cost to Ukrainian, Moldovan, and Kyrgyz citizens with opioid dependence. The BI will last approximately 20 minutes and time will be made available for them to ask questions. The BI will not be audio recorded.

Screening, Brief Intervention, & Referral to Treatment (SBIRT) Program

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age or older
• Within 180 days of release or possible release (eligible for parole) to the community, but greater than 7 days to release to the community OR currently in probation.
• Meets ICD-10 screening criteria for pre-incarceration opioid dependence
• FOR THOSE IN PROBATION:
• Living within 30 km of an OAT delivery site
• Not having received OAT in the last 15 days.
• Positive for OUD

You may not qualify if:

• Pregnant or may become pregnant
• FOR THOSE IN PRISON: Will be released from prison in 7 days or less.

Sponsors & Collaborators

• Yale University: lead
• Ukrainian Institute on Public Health Policy: collaborator
• AFEW Kyrgyzstan: collaborator
• AFI - Act For Involvement: collaborator
• National Institute on Drug Abuse (NIDA): collaborator

Study Sites (3)

AIDS Foundation East-West

Bishkek, Kyrgyzstan

Location

AFI - Act for Involvement

Chisinau, Moldova

Location

Ukrainian Institute for Public Health Policy

Kyiv, Ukraine

Location

MeSH Terms

Conditions

Opioid-Related Disorders; HIV Infections; Tuberculosis; Hepatitis C; Hepatitis B; Depression; Syphilis

Condition Hierarchy (Ancestors)

Narcotic-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders; Blood-Borne Infections; Communicable Diseases; Infections; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Mycobacterium Infections; Actinomycetales Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Hepatitis, Viral, Human; Flaviviridae Infections; Hepatitis; Liver Diseases; Digestive System Diseases; Hepadnaviridae Infections; DNA Virus Infections; Behavioral Symptoms; Behavior; Treponemal Infections; Spirochaetales Infections; Gram-Negative Bacterial Infections; Sexually Transmitted Diseases, Bacterial

Study Officials

• Frederick L Altice, MD

  Yale University

  PRINCIPAL INVESTIGATOR

• Natalya Shumskaya

  AIDS Foundation East-West

  STUDY DIRECTOR

• Nataliia Saishuk

  Ukrainian Institute for Public Health Policy

  STUDY DIRECTOR

• Svetlana Doltu

  AFI - Act For Involvement

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 23, 2021
• First Posted: July 1, 2021
• Study Start: January 1, 2017
• Primary Completion: April 30, 2023
• Study Completion: April 30, 2023
• Last Updated: May 11, 2025

Record last verified: 2025-05

Locations

MO (1); UA (1); KY (1)